Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Formulary Drug Review: Edaravone.

Hospital pharmacy·2017

Same author

Formulary Drug Review: Ocrelizumab.

Hospital pharmacy·2017

Same journal

Microreactors for continuous processing – How close to commercial utility?

Current opinion in drug discovery & development·2010

Same journal

Synthesis of polyketide natural products and analogs as promising anticancer agents.

Current opinion in drug discovery & development·2010

Same journal

Enantioselective synthesis of substituted oxindoles and spirooxindoles with applications in drug discovery.

Current opinion in drug discovery & development·2010

Same journal

Eliminating pharmaceutical impurities: Recent advances in detection techniques.

Current opinion in drug discovery & development·2010

Same journal

Stereoselective heterocycle synthesis through oxidative carbon-hydrogen bond activation.

Current opinion in drug discovery & development·2010

Same journal

Catalysis in aqueous media for the synthesis of drug-like molecules.

Current opinion in drug discovery & development·2010

See all related articles

Search research articles

Related Experiment Videos

CYP2C9 polymorphisms: considerations in NSAID therapy.

Zaynah K Ali¹, Rebekah J Kim, Francis M Ysla

¹University of California, Berkeley, Department of Nutritional Sciences and Toxicology, CA 94720-3104, USA. pnapluza@berkeley.edu

Current Opinion in Drug Discovery & Development

|January 20, 2009

Summary

This summary is machine-generated.

Genetic profiling can accelerate drug safety assessments and personalize medicine. Identifying genetic variants, like those in cytochrome P450 2C9, helps predict adverse drug reactions and optimize treatment for better patient outcomes.

Related Experiment Videos

Area of Science:

Pharmacogenomics
Drug Metabolism
Clinical Trial Safety

Background:

Drug development faces safety hurdles, necessitating faster toxicity identification.
Individual genetic variability is key to predicting adverse drug effects, especially across diverse populations.
Current drug safety protocols require enhancement for efficiency and patient-specific care.

Purpose of the Study:

To highlight the importance of genetic variability profiling in drug safety.
To propose pharmacogenomic screening as a method for predicting adverse drug reactions.
To emphasize the role of genetic polymorphisms in drug metabolism and patient management.

Main Methods:

Review of existing literature on drug safety and genetic variability.
Analysis of cytochrome P450 (CYP) 2C9 polymorphisms as a case study.
Discussion of the implications of genetic variants on drug clearance and efficacy.

Main Results:

Genetic profiling offers a faster route to identifying potential drug toxicities.
CYP2C9 polymorphisms (CYP2C9*2, CYP2C9*3) affect metabolic clearance of drugs.
Variant alleles lead to reduced drug metabolism compared to wild-type (CYP2C9*1).

Conclusions:

Integrating genetic variability screening into drug development can improve safety and efficacy.
Personalized dosing strategies based on genetic profiles can reduce medical costs and enhance treatment success.
Considering CYP polymorphisms is crucial for developing safer and more effective NSAIDs, particularly for aging populations with inflammatory conditions.